DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2036
INDEX
Hypobetalipoproteinemia, 891
Hypocalcemia, 1288
treatment of, 1291
Hypocarbia, 562
Hypoglycemia, 1270–1272
drugs causing, 1248t
persistent hyperinsulinemic, of
infancy, 104t
Hypogonadism, female, 1203
Hypoparathyroidism, vitamin D for,
1293
Hypoprothrombinemia, drug- and
venom-induced, 874
Hypoprothrombinemia of the newborn,
873–874
Hypotension
ACE inhibitors and, 735
sympathomimetic drugs for,
301–302
Hypothalamic-pituitary-adrenal (HPA)
axis, 1104–1105
clinical disorders of, 1120–1123
Hypothermia, with general anesthesia,
532
Hypothyroidism, 1141, 1143
congenital, 1145
and dyslipidemia, 890t
in pregnancy, 1144
subclinical, 1144
Hypoxanthine guanine phosphoribosyl
transferase (HGPRT), 139,
1702
Hypoxemia, pulmonary mechanisms
of, 556
Hypoxia
adaptation to, 558–559
cardiovascular effects of, 558
cellular effects of, 558
correction of, 560
effects of, 556–559
metabolic effects of, 558
neurological effects of, 558
nonpulmonary causes of, 556
pulmonary, 556
respiratory effects of, 558
Hypoxia-inducible factor (HIF), 140
HYTONE (hydrocortisone cream), 1225t
I
Ibandronate, pharmacokinetics of,
1849t
Ibopamine, for heart failure, 805
IBUDONE, 988
Ibuprofen, 987
absorption, 988
Ibuprofen (Cont.):
adverse effects and side effects of,
988
compared to aspirin, 968t
COX isoform selectivity, 962f
distribution of, 988
dosage and administration of, 968t
elimination, 988
metabolism of, 128t
pharmacokinetics of, 968t, 988,
1850t
pharmacology of, 962f
plasma pharmacokinetics of, 962f
structure of, 988f
therapeutic uses of, 968t, 988
Ibutilide
antiarrhythmic use of, 835t, 841
arrhythmias caused by, 821t
contraindications to, 833t
dosage and administration of, 835t,
841
electrophysiological actions of, 829t
mechanism of action of, 830
pharmacokinetics of, 835t
structure of, 841
Icatibant, 930, 932
ICCS. See Interstitial cells of Cajal
(ICCs)
Ichthyosis
keratolytics for, 1829
retinoids for, 1811
Idiosyncratic reactions, 76–77
Idoxifene, 1756
Idoxuridine, 1596t, 1604–1605
Idoxuridine ophthalmic solution, 1153t
Idrabiotaparinus, 858
Idraparinux, 858
Idrarubicin, pharmacokinetics of, 1850t
Ifosfamide, 1668t–1670t
toxicity of, extramedullary, 1682t
ILARIS (canakinumab), 961
Ileus, paralytic, anticholinesterase
agents for, 250
Ilieus, post-operative, 1335
Iloperidone
dosage of, 425t
metabolism of, 433t
side effects of, 425t
Iloprost, 952
Imatinib mesylate
ABC transporters and, 106t
chemistry, 1732
mechanism of action of, 1732
pharmacokinetics of, 1733–1734,
1850t
Imatinib mesylate (Cont.):
resistance, mechanisms of,
1732–1733, 1733f
structure of, 1732
therapeutic uses of, 1732, 1734
toxicity of, 1734
Imatinib (STI-565), 1668t–1670t
IMDUR (isosorbide-5-mononitrate),
754t
Imidazoles, 1576, 1817–1818
for ophthalmic use, 1784t
for topical use, 1586–1587
IMiDs. See Immunomodulatory
analogs
Iminostilbenes, 594–596
Imipenem, pharmacokinetics of, 1851t
Imipramine
adrenergic receptors and, 206t
disposition of, 409t
dose and dosage forms of, 400t
metabolism of, 128t
potencies
at human transporters for
monamine neurotransmitters,
406t
at neurotransmitter receptors,
410t
side effects of, 400t
Imiquimod, 1596t, 1617–1618
adverse effects and side effects of,
1823
for cutaneous viral infections, 1818
in dermatology, 1823
for genital warts, 1823
mechanism of action of, 1820t
structure of, 1823
Immune globulins, 1023–1024
Immune response, 1005–1006
eicosanoids and, 948, 949–950
Immunization, 1023–1024
Immunoglobulin(s)
in anaphylactic reactions, 76
in arthrus reactions, 76
in cytolytic reactions, 76
intravenous, in dermatology, 1827
Immunomodulators, topical, for
pruritus, 1828t
Immunomodulatory agents, for
ophthalmic use, 1790
Immunomodulatory analogs. See also
Lenalidomide; Thalidomide
in cancer treatment, 1740–1742
Immunomodulatory therapy,
1054–1058
Immunostimulation, 1021–1024